Human Isoprenoid Pathway Inhibitors as Novel Antibiotic Adjuvants
- Detailed Technology Description
- None
- Others
-
- *Abstract
-
Boosting the effectiveness of an antibiotic is a critical component in the fight against infectious disease. This technology is based on the ability to exploit a microorganism’s metabolic pathways to make them more susceptible to standard antibiotics. It has been shown that disrupting the biosynthetic pathway of isoprenoids (compounds related to cholesterol synthesis) in microorganisms makes them more susceptible to antibiotic treatment. This adjuvant therapy may provide a means to reduce the over-use of antibiotics that has led to the evolution of antibiotic-resistant bacterial strains.
Benefits:
May provide a new weapon to fight infections by increasing microbial susceptibility to antibiotics.
May lower overall treatment costs by lowering required dosages of antibiotics.
Relatively low regulatory hurdles: several drugs that affect the isoprenoid biosynthesis pathway in humans are already FDA- approved.Applications:
Medical infectious disease therapy for recalcitrant infections such as Lyme disease or MRSA.
Auxiliary treatment for veterinary antibiotic regimens to lower levels of antibiotics used in animals for dairy and meat consumption.
- Country/Region
- USA
